Chad Tang

Chad Tang is an Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center. His research focuses on oligometastatic prostate and renal cell carcinoma, stereotactic ablative radiation therapy, and metastasis-directed therapy. He leads the X-MET collaboration, developing clinical tools such as the CEREBRO risk estimator and contributing to the WOLVERINE meta-analysis in The Lancet Oncology. His recent work includes prognostic biomarkers like KIM-1 and circulating tumor DNA, the IROCK contouring guidelines, and trials combining stereotactic body radiotherapy with androgen receptor pathway inhibitors.